CG Oncology (CGON) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CGON CG Oncology

Watchlist

30.810
+1.840+6.35%

Close May 22 16:00 ET

2.05BMarket Cap-28396P/E (TTM)

Pre-Market

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Decoding 10 Analyst Evaluations For CG Oncology
In the latest quarter, 10 analysts provided ratings for CG Oncology (NASDAQ:CGON), showcasing a mix of bullish and bearish perspectives.The following table provides a quick overview of their recent ra
BenzingaMay 14 13:00 ET
CG Oncology Price Target Raised to $50.00/Share From $43.00 by Goldman Sachs
CG Oncology Price Target Raised to $50.00/Share From $43.00 by Goldman Sachs
Dow JonesMay 14 08:51 ET
Goldman Sachs Upgrades CG Oncology to Buy From Neutral With $50 Price Target
CG Oncology (CGON) has an average outperform rating and a price target range of $50 to $86, according to analysts polled by Capital IQ.
MT NewswiresMay 14 07:53 ET
CG Oncology Raised to Buy From Neutral by Goldman Sachs
CG Oncology Raised to Buy From Neutral by Goldman Sachs
Dow JonesMay 13 16:36 ET
Express News | Goldman Sachs Upgrades CG Oncology to Buy, Announces $50 Price Target
BenzingaMay 13 16:25 ET
CG Oncology Expects Cash Runway to Be Sufficient to Fund Ops Through 2027 >CGON
CG Oncology Expects Cash Runway to Be Sufficient to Fund Ops Through 2027 >CGON
Dow JonesMay 9 08:10 ET

Comments

Meltyy

Yesterday 15:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics(IOVA.US)$ Phase 2
$Supernus Pharmaceuticals(SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US)$ Phase 2a
$MorphoSys(MOR.US)$ Phase 2
$Nuvation Bio(NUVB.US)$ Phase 2
$ALX Oncology(ALXO.US)$ Phase 2
$BioXcel Therapeutics(BTAI.US)$ Phase 2
$Purple Biotech(PPBT.US)$ Phase 2
$Arcus Biosciences(RCUS.US)$ Phase 2
$Medicenna Therapeutics(MDNAF.US)$ Phase 2b
$Affimed NV(AFMD.US)$ Phase 2
$Barinthus Biotherapeutics(BRNS.US)$ Phase 2b...

Meltyy

Apr 18 03:34

🎯 Ph 3 readouts in Q2 2024...

$Travere Therapeutic(TVTX.US)$ Phase 3
$CG Oncology(CGON.US)$ Phase 3
$United Therapeutics(UTHR.US)$ Phase 3
$United Therapeutics(UTHR.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Insmed(INSM.US)$ Phase 3
$GlycoMimetics(GLYC.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$UroGen Pharma Ltd(URGN.US)$ Phase 3
$Lyra Therapeutics(LYRA.US)$ Phase 3
$Citius Pharmaceuticals(CTXR.US)$ Phase 3
$Jaguar Health(JAGX.US)$ Phas...

Meltyy

Apr 1 02:47

Biotech Stock Catalyst Watchlist

🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies(ITCI.US)$ Phase 3
$CG Oncology(CGON.US)$ Phase 3
$Hutchmed (China)(HCM.US)$ Phase 3
$Viracta Therapeutics(VIRX.US)$ Phase 3
$GlycoMimetics(GLYC.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$UroGen Pharma Ltd(URGN.US)$ Phase 3
$Lyra Therapeutics(LYRA.US)$ Phase 3
$Citius Pharmaceuticals(CTXR.US)$ Phase 3
$Marinus Pharmaceuticals(MRNS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3...

Moomoo AI

Jan 26 10:59

CG Oncology's successful IPO hints at a possible resurgence of investor interest in biotech stocks, despite the sector's recent underperformance. This strong debut is viewed as a positive indicator for the sector's future.

Biotech's First IPO of 2024 Popped 96%. Good Times Could Be Ahead for the Stocks. -- Barrons.com

Moomoo AI

Jan 25 14:11

The successful IPO of CG Oncology and its strong performance on debut indicates a revival in the market for initial public offerings, which could be a positive sign for other companies planning to go public.